Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
11/2007
11/20/2007US7297715 PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
11/20/2007US7297696 Antiarthritic agents; antihistamines; atherosclerosis; multiple sclerosis; Crohn's disease; nephritis; pancreastitis; skin disorders; restenosis; prevent leukocyte migration
11/20/2007US7297694 central nervous system disorders; traumas; anticancer agents; neurodegenerative agents; analgesics; headaches and cardiovascular disorders
11/20/2007US7297693 furan-, pyrrole- or thiophenecarboxamides ring-substituted with a hydroxyimino-fused ring and a nitrogen heteroarene; e.g., 5-[5-(1-Morpholin-4-yl-methanoyl)-2-pyridin-4-yl-furan-3-yl]-indan-1-one oxime;treating neurotraumatic diseases, cancer, neurodegeneration, pain, migraine and cardiac hypertrophy
11/20/2007US7297692 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them
11/20/2007US7297538 Apparatus for use in cell transplantation
11/20/2007US7297523 Human elongase genes and uses thereof
11/20/2007US7297346 For therapy of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain attention deficit hyperactivity disorder and fatigue
11/20/2007US7297099 Use of osteopontin for the treatment and/or prevention of neurologic diseases
11/20/2007CA2341410C Hydrogel compositions for the controlled release administration of growth factors
11/20/2007CA2300289C A pharmaceutical composition active in reducing production of mcp-1 protein
11/20/2007CA2295746C Composition comprising l-carnitine or an alkanoyl l-carnitine and long-chain alkanols
11/20/2007CA2262409C Modified tie-2-receptor ligands
11/20/2007CA2206362C Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
11/16/2007CA2554386A1 Combinations of hmg coa reductase inhibitors and negatively charged phospholipids and uses thereof
11/15/2007WO2007131179A1 Factor xa inhibitors
11/15/2007WO2007130627A2 Il-33 in the treatment and diagnosis of diseases and disorders
11/15/2007WO2007130509A2 Pyrroloquinoline quinones and use thereof
11/15/2007WO2007130075A1 Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
11/15/2007WO2007129743A1 Anti-inflammatory composition
11/15/2007WO2007129646A1 Macrolide derivative
11/15/2007WO2007129618A1 Inhibitor of neutrophil activation/migration factor and use thereof
11/15/2007WO2007129149A1 Use of cyclosporin a or melle4-cyclosporin for the treatment of acute myocardial infarction
11/15/2007WO2007129019A1 Sulfonamide compounds useful as edg receptor modulators
11/15/2007WO2007128761A2 Uses of dpp-iv inhibitors
11/15/2007WO2007128568A1 Bicyclic derivatives as cetp inhibitors
11/15/2007WO2007128454A1 3-tetrazolyl indazoles, 3-tetrazolyl pyrazolopyridines, and use thereof
11/15/2007WO2007128344A1 Design and synthesis of biotinylated probes for n-acyl-ethanolamines
11/15/2007WO2007128088A2 Use of n-aminoimidazole cytoprotective compounds for treating cell death and/or gsk-3 mediated diseases
11/15/2007WO2007106554A3 Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds
11/15/2007WO2007098390A3 Method for treating resistant hypertension
11/15/2007WO2007076379A3 4,7-dihydrothieno[2,3-b]pyridine compounds and pharmaceutical compositions
11/15/2007WO2007067836A3 Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors
11/15/2007WO2006138537A3 Ex vivo blood treatment with renal epithelial cells in cardiorenal and hepatorenal syndrome
11/15/2007WO2006086456A3 Combination of organic compounds
11/15/2007WO2003018754A3 Neural regeneration peptide and methods for their use in treatment of brain damage
11/15/2007WO2002089799A3 Use of dihydropyrazoles to increase erythropoietin and vasculari zation
11/15/2007US20070265449 Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity
11/15/2007US20070265349 Medicinal association of a biguanine and a carrier, for example metformin and arginine
11/15/2007US20070265348 Therapeutic guanidines
11/15/2007US20070265345 Novel Biphenyl Compounds And Their Use
11/15/2007US20070265328 2-(6-oxo-1,7-diaza-spiro[4.4]non-7-yl)-propionamides such as 4-(S)-hydroxy-5-(S)-[2-(S)-(1-isobutyl-6-oxo-1,7-diaza-spiro(S)-[4.4]non-7-yl)-propionylamino]-2-(R)-methyl-6-phenyl-hexanoic acid butylamide; inhibitors of aspartic proteases such as beta-secretase
11/15/2007US20070265327 For therapy of neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal
11/15/2007US20070265325 Nitro Indazole Derivatives
11/15/2007US20070265323 Compounds for the treatment of metabolic disorders
11/15/2007US20070265322 Compounds for the treatment of metabolic disorders
11/15/2007US20070265320 (2S,4S)-1-[[(4-carbamoylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile, for treating type II diabetes; increase glucagon-like peptide activity
11/15/2007US20070265319 Neuroprotectants; reduce side effect of neurotoxic agent; treatment of neuropathies resulting from chemotherapeutic agents used in the treatment of HIV and proliferative disease such as cancer and treatment of inflammatory diseases, neurodegenerative diseases
11/15/2007US20070265308 5-[5-(2-chloro-4-fluorophenyl)-2-piperidin-4-yl-1,3-thiazol-4-yl]-1-(2,6-dichlorophenyl)pyridin-2(1H)-one; p38 MAP kinase inhibitory activity; inflammatory, respiratory , circulatory and central nervous diseases; rheumatoid arthritis
11/15/2007US20070265299 Compounds for the treatment of inflammatory disorders
11/15/2007US20070265294 Formulations and methods for vascular permeability-related diseases or conditions
11/15/2007US20070265286 Quinazoline derivatives as VEGF inhibitors
11/15/2007US20070265282 Use of ticagrelor treating myocardial infarction, thrombotic stroke, angina and transient ischemic attacks
11/15/2007US20070265280 Methods of using sodium channel blockers
11/15/2007US20070265278 2-phenyl-indoles as prostaglandin d2 receptor antagonists
11/15/2007US20070265273 Pyrimidin-2-Amine Derivatives and Their Use as A2b Adenosine Receptor Antagonists
11/15/2007US20070265264 Thia-tetraazaacenaphthylene kinase inhibitors
11/15/2007US20070265263 Heterocyclic inhibitors of ERK2 and uses thereof
11/15/2007US20070265260 Quinazoline derivatives
11/15/2007US20070265259 Proline Derivatives
11/15/2007US20070265244 2-[1-(1-carboxymethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylcarbamoyl)-cyclopentylmethyl]-N-(3-dimethylamino-propyl)-N-methyl-succinamic acid, or a biolabile ester thereof; neutral endopeptidase and/or human soluble endopeptidase (hSEP) inhibitors; cardiovascular diseases, apoptosis e.g. stroke
11/15/2007US20070265228 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis
11/15/2007US20070265223 Compositions and methods of enhancing survivability and reducing injury of cells, tissues, organs, and organisms under hypoxic or ischemic conditions
11/15/2007US20070265217 Single Nucleotide Polymorphisms as Prognostic Tool to Diagnose Adverse Drug Reactions (Adr) and Drug Efficacy
11/15/2007US20070265208 Association of calpain inhibitors and reactive oxygen species trapping agents
11/15/2007US20070265206 Cyclic Natriuretic Peptide Constructs
11/15/2007US20070265201 Inhibitors of inflammatory cytokine transcription derived from hcmv protein ie2
11/15/2007US20070265196 Method of Modulating Pro-Inflammatory and Inflammatory Activity Mediated by C-Reactive Protein
11/15/2007US20070264417 Procyanidins; cleaning cocoa beans, heating unroasted cocoa nibs to loosen shells, winnowing the nibs from the shells, extracting with a polar solvent, a non-polar solvent, or a supercritical fluid
11/15/2007US20070264373 Toxin Induced Sympathectomy
11/15/2007US20070264345 liquid crystal gel containing polyoxyethylene-glyceryl-trioleate, 26.7-40.0%, propylene-glycol, 13.3-20.0%, isopropyl myristate, 5.0-35.0%, ethanol, 0.01-10.0%, benzyl alcohol, 0.5-1.5%, a hyaluronic acid salt or complex 0.01-2.00%, and purified water, 12.5-26.5%; healing cosmetics
11/15/2007US20070264336 Hydrophilic/lipophilic polymeric matrix dosage formulation
11/15/2007US20070264276 Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases
11/15/2007US20070264254 Cardiac muscle function and manipulation
11/15/2007US20070264249 Gene-based lipid hydrolysis therapy for atherosclerosis and related diseases
11/15/2007US20070264246 ENHANCED MEDICAL TREATMENTS RESULTING FROM CHEMICAL IDENTIFICATION OF CALCIUM INFLUX FACTOR, IDENTITY WITH THE FACTOR ACTIVATING PHOSPHOLIPOLYSIS AND PRECIPITATING SUDDEN DEATH DURING MYOCARDIAL INFARCTION, AND DETERMINATION OF SIMILAR ACTIVATING MECHANISMS IN MULTIPLE CELL TYPES THROUGH DISINHIBITION OF CALCIUM-INDEPENDENT PHOSPHOLIPASE A2beta
11/15/2007US20070264245 Compositions and minimally invasive methods for treating incomplete tissue repair
11/15/2007US20070264232 Cell populations which co-express CD49c and CD90
11/15/2007US20070264230 Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands
11/15/2007US20070264195 Modulation of Activity of Neurotrophins
11/15/2007US20070264194 Peptides That Bind To Atherosclerotic Lesions
11/15/2007DE102007017298A1 New nanoparticles containing nicotine and/or cotinine useful e.g. for cigarette weaning and to treat e.g. attention-deficit hyperactivity disorder, Parkinson's disease, Alzheimer's disease and Binswanger's disease
11/15/2007CA2833705A1 Use of dpp iv inhibitors
11/15/2007CA2651556A1 3-tetrazolylindazoles and 3-tetrazolylpyrazolopyridines and their use
11/15/2007CA2651303A1 Factor xa inhibitors
11/15/2007CA2651019A1 Uses of dpp iv inhibitors
11/15/2007CA2650954A1 Bicyclic derivatives as cetp inhibitors
11/15/2007CA2618646A1 Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
11/14/2007EP1854892A1 Modified viral surface proteins wich bind to cells of tumor vasculature
11/14/2007EP1854880A1 Methods and reagents for modulating cholesterol levels
11/14/2007EP1854787A1 Novel cyclic compound having quinolylalkylthio group
11/14/2007EP1854780A1 Method of producing chlorogenic acid composition
11/14/2007EP1854471A1 Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
11/14/2007EP1853566A1 Cinnoline compounds and their use as liver x receptor modulators
11/14/2007EP1853316A1 Use of an antagonist of epac for treating human cardiac hypertrophy
11/14/2007EP1853296A1 Use of a cyclic undecapeptide for the preparation of a medicament for administration during myocardial ischaemic events
11/14/2007EP1853290A1 Anti-hypertensive dietary supplement derived from salmo or oncorhynchus protein hydrolysates
11/14/2007EP1853280A2 Compositions and methods for treating and preventing cardiomyopathy and heart disease
11/14/2007EP1853271A2 Method and composition for treating peripheral vascular diseases
11/14/2007EP1853270A1 Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
1 ... 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 ... 1595